KalVista Pharmaceuticals (KALV) TD Cowen 45th Annual Healthcare Conference summary

Key clinical and market insights

• Sebetralstat is under review by the FDA and six other authorities as the first oral on-demand therapy for hereditary angioedema (HAE), with a PDUFA date of June 17.

• Clinical data show efficacy across all attack types and severities, including laryngeal and mild attacks, and in adolescents aged 12 and up.

• Physicians express strong enthusiasm due to robust data and unmet needs, especially among poorly controlled prophylaxis users.

• The product is expected to see early adoption among patients with high attack rates despite prophylaxis, followed by on-demand-only users.

• Market opportunity is significant, with estimates of 85,000+ attacks treated annually and potential for increased treatment rates with oral therapy.

Commercial launch and preparedness

• Extensive clinician education and engagement are underway, targeting both top prescribers and broader physician groups.

• Sales and field teams have been onboarded, with high levels of physician outreach and a patient services hub being established.

• Supply chain logistics and specialty pharmacy networks are being finalized to ensure efficient drug delivery.

• Patient awareness campaigns and unbranded activities have generated significant interest, with over 1,600 patients opting in for updates.

• Launch is expected to see a bolus of early adopters, not just gradual uptake, due to proactive physician and patient engagement.

Payer, pricing, and access strategy

• Pre-approval discussions with about 60 payers have been positive, with no significant concerns about generic competition impacting pricing or access.

• Prior authorizations are standard but not expected to be a major hurdle; a quick start program will provide initial drug supply during coverage processing.

• Pricing is expected at a premium to FIRAZYR (approx. $11,000 per dose), but positioned to balance payer acceptance and broad access.

• The label is anticipated to be straightforward, similar to FIRAZYR, with a maximum daily dosing limit.